Review on patents for ubiquitin-proteasome inhibitor as medical advance in major human diseases

Recent Patents on Biomedical Engineering

Volumn 2, Issue 3, 2009, Pages 180-192

  Zhu, Yongqiang ^a   Gao, Qingzhi ^b  

^a Jiangsu Key Laboratory of Molecular Targeted Antitumor Drug Research   (China)

^b TIANJIN UNIVERSITY   (China)

Author keywords

Anticancer drug; Antivirus; Cardiovascular disease; Diabetes; Neurodegenerative disease; Proteasomes inhibitor; Ubiquitin proteasome pathway (UPP)

Indexed keywords

ANTI VIRUS; ANTICANCER DRUG; CARDIO-VASCULAR DISEASE; NEURODEGENERATIVE DISEASE; PROTEASOMES; UBIQUITIN;

DEREGULATION; PATENTS AND INVENTIONS;

PROTEINS;

EID: 77951644991     PISSN: 18747647     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874764710902030180     Document Type: Review

References (181)

1. Ciechanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 1978; 81: 1100-1105.
2. Ciechanover A, Heller H, Elias S, Haas AL, Hershko A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci USA 1980; 77: 1365-1368.
3. Hershko A, Ciechanover A. Mechanisms of intracellular protein breakdown. Annu Rev Biochem 1982; 51: 335-364.
4. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
5. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
6. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70: 503-533.
7. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15: 435-467.
8. Verma R, Deshaies RJ. A proteasome howdunit: The case of the missing signal. Cell 2000; 101: 341-344.
9. Arrigo AP, Tanaka K, Goldberg AL, Welch WJ. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 1988; 331: 192-194.
10. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-847.
11. Groll M, Ditzel L, Löwe J, et al. Structure of 20S proteasome from yeast at 2.4Å resolution. Nature 1997; 386: 463-471.
12. Cardozo C, Michaud C, Orlowski M. Components of the bovine pituitary multicatalytic proteinase complex (proteasome) cleaving bonds after hydrophobic residues. Biochemistry 1999; 38: 9768-9777.
13. Dick TP, Nussbaum AK, Deeg M, et al. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem 1998; 273: 25637-25646.
14. Orlowski M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry 1990; 29: 10289-10297.
15. Rivett A. Proteasomes: Multicatalytic proteinase complexes. Biochem J 1993; 291: 1-10.
16. Voges D, Zwickl P, Baumeister W. The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68: 1015-1068.
17. Löwe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the Archaeon T. acidophilum at 3.4Å resolution. Science 1995; 268: 533-539.
18. Larsen CN, Finley D. Protein translocation channels in the proteasome and other proteases. Cell 1997; 91: 431-434.
19. Baumeister W, Walz J, Zühl F, Seemüller E. The proteasome: Paradigm of a self-compartmentalizing protease. Cell 1998; 92: 367-380.
20. Brannigan JA, Dodson G, Duggleby HJ, et al. A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature 1995; 378: 416-419.
21. Wilk S, Orlowski M. Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. J Neurochem 1980; 35: 1172-1182.
22. Orlowski M, Wilk S. A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin containing peptides. Biochem Biophys Res Commun 1981; 101: 814-822.
23. Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides generated from protein by mammalian 26S and 20S proteasome. J Biol Chem 1999; 274: 3363-3371.
24. Nussbaum AK, Dick TP, Keilholz W, et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA 1998; 95: 12504-12509.
25. Delcros JG, Baudy FM, Prigent C, Arlot BY. Proteasome inhibitors as therapeutic agents: Current and future strategies. Curr Med Chem 2003; 10: 479-503.
26. Isamu, S.: WO2009035020 (2009).
27. Nathan, C., Lin, G.: WO2009026579 (2009).
28. Olhava, E.J., Danca, M.D.: WO2009020448 (2009).
29. Zhou, H.J., Laidig, G.J., Shenk, K.D., Sun, C.C.M.: WO2008140782 (2008).
30. Olhava, E.J., Danca, M.D.: US200807442830 (2008).
31. Palladino, M., Anderson, K.C., Chauhan, D., Chandra, J., Mcconkey, D.: WO2008124699 (2008).
32. Shenk, K.D., Parlati, F., Zhou, H.J., Sylvain, C., Smyth, M.S., Bennett, M.K., Laidig, G.J.: WO2007149512 (2007).
33. Gordon, N.C., Kelley, R.F., Pham, A., Hymowitz, S.: WO2007120334 (2007).
34. Zhou, H.J., Sun, C.M., Shenk, K.D., Laidig, G.J.: WO2007056464 (2007).
35. Corey, E.J., Hogan, P.C.: WO2007033039 (2007).
36. Johann, L., Martin, K.: WO2007017284 (2007).
37. Oliva, A., Bernardnini, R., D'Arasmo, G., Cassara, P.G., Bernareggi, A., Menta, E.: WO2006086600 (2006).
38. Palladino, M., Potts, B.C., Macherla, V.R.R., Neuteboom, S.T.C.: WO2006060809 (2006).
39. Potts, B.C., Macherla, V.R.R., Mitchell, S.S., Manam, R.R., Reed, K.A., Lam, K.S., Neuteboom, S.T.C., Chao, T.H., Nicholson, B., Billstrom, C.: WO2006028525 (2006).
40. Chan, T.H., Lam, W.H., Chow, L.M.C., Dou, Q., Kuhn, D.J., Kazi, A., Wan, S.B., Landis, P.K.R.: WO2006017981 (2006).
41. Smyth, M.S., Laidig, G.J., Borchardt, R.T., Bunin, B.A., Crews, C.M., Musser, J.H., Schneekloth, J.S.J., Chabala, J.C.: WO2005105827 (2005).
42. Iinuma, H., Momose, I.: WO2005105826 (2005).
43. Deshaies, R., King, R., Verma, R.: WO2005025515 (2005).
44. Bernareggi, A., Cassara, P.G., Chatterjee, S., Ferretti, E., Iqbal, M., Menta, E., Messina, M. P.A., Oliva, A.: WO2005021558 (2005).
45. Chatterjee, S., Iqbal, M., Menta, E., Oliva, A.: WO2005016859 (2005).
46. Stadler, M., Seip, S., Müller, H., Mayer, B.A., Brüning, M.A., Benet, B.J., Togame, H., Dodo, R. Reinemer, P., Bacon, K., Fuchikami, K., Matsukawa, S., Urbahns, K.: WO2004071382 (2004).
47. Purandare, A.V., Laing, N.M.: WO2004064755 (2004).
48. Mitchell, S.S., Nicholson, B.: WO2004034970 (2004).
49. Agoulnik, S., Akasaka, K., Fang, F., Harmange, J.C., Hawkins, L., Jiang, Y., Johannes, C., Li, X.Y., Mcguinness, P., Murphy, E., Schiller, S., Vermeulen, M., Wu, J.Y.: WO03059898 (2003).
50. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
51. Adams J. Proteasome inhibition: A novel approach to cancer therapy. Trends Mol Med 2002; 8 (4 Suppl): S49-S54.
52. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
53. Pham L, Tamayo A, Lo P, Yoshimura L, Ford RJ. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 2001; 98: 465a.
54. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006; 14: 451-456.
55. Adams J, Behnke M, Chen SW, et al. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8: 333-338.
56. Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003; 29(1): 21-31.
57. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 2005; 45: 465-476.
58. Adams, J., Ma, Y.T., Stein, R., Baevsky, M., Grenier, L., Plamondon, L.: WO9613266 (1996).
59. Brand, S., Goldberg, A.L., Plamondon, L., Soucy, F.: WO9835691 (1998).
60. Shyjan, A.W., Macbeth, K.J.: WO9925373 (1999).
61. Plamondon, L., Adams, J., Grenier, L., Guptashanker, L.: WO02059130 (2002).
62. Zhang, Y.P., Huang, A., Luo, B., Wang, J.K.: WO2009026430 (2009).
63. Venkata, P.R., Rajasekhar, K., Veerender, M., Amarendhar, M., Nageshwar, G., Rao, P.R., Mallesha, H., Naidu, M.N., Kumar, R.S.: WO2009036281 (2009).
64. Janca, M., Dobrovolny, P.: WO2009004350 (2009).
65. Pickersgill, I. F., Bishop, J., Koellner, C., Gomez, J.M., Geiser, A., Hett, R., Ammoscato, V., Munk, S., Lo, Y., Chui, F.T., Kulkarni, V.R.: WO2005097809 (2005).
66. Ravi, J.R.R., Pulla, R.M., Adibatla, K.S.B.R., Benkaiah, C.N.: WO2008075376 (2008).
67. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed 2003; 42: 355-357.
68. Margalef IV, Rupnicki L, Lam HW. Formal synthesis of salinosporamide A using a nickel-catalyzed reductive aldol cyclization-lactonization as a key step. Tetrahedron 2008; 64: 7896-7901.
69. Takahashi K, Midori M, Kawano K, Ishihara J, Hatakeyama S. Entry to heterocycles based on indium-catalyzed Conia-Ene reactions: Asymmetric synthesis of (-)-salinosporamide A. Angew Chem Int Ed 2008; 47: 6244-6246.
70. Caubert V, Masse J, Retailleau P, Langlois N. Stereoselective formal synthesis of the potent proteasome inhibitor: Salinosporamide A. Tetrahedron Lett 2007; 48: 381-384.
71. Corey, E.J.: WO2005113558 (2005).
72. Corey, E.J.: WO2005099687 (2005).
73. Mulholland NP, Pattenden G, Walters IAS. A concise and straightforward total synthesis of (+/-)-salinosporamide A, based on a biosynthesis model. Org Biomol Chem 2008; 6: 2782-2789.
74. Manam RR, Macherla VR, Potts BCM. Stereoselective enzymatic reduction of keto-salinosporamide to (-)-salinosporamide A (NPI-0052). Tetrahedron Lett 2007; 48: 2537-2540.
75. Groll M, Huber R, Potts BC. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006; 128: 5136-5141.
76. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-419.
77. Cusack JC, Liu R, Xia L, et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006; 12: 6758-6764.
78. Miller B, Bahjat R, Chao TH, et al. Development of a structurally and biologically novel, oral proteasome inhibitor. Proc Am Assoc Cancer Res 2004; 45.
79. Padrik P, Price TJ, Spear MA, et al. Phase 1 study of the novel proteasome inhibitor NPI-0052 in patients with advanced magligances including leukemias. Ann Oncol 2008; 19: 153-165.
80. Giuliano M, Lauricella M, Calvaruso G, et al. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 1999; 59: 5586-5595.
81. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003; 102: 3765-3774.
82. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008; 111: 4752-4763.
83. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008; 111: 1654-1664.
84. Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007; 110: 267-277.
85. Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: A mechanism for synergy in leukemia cells. Blood 2009; 113(18): 4289-4299.
86. Mitchell, S.S., Nicholson, B.: WO2004034970 (2004).
87. Myers, A.G., Sun, B.Y., Jackson, S.R.: WO2007021897 (2007).
88. Potts, B.C., Macherla, V.R.R., Mitchell, S.S., Manam, R.R., Reed, K.A., Lam, K.S., Neuteboom, S.T.C., Chao, T.H., Nicholson, B., Billstrom, C.: WO2006028525 (2006).
89. Palladino, M., Potts, B.C., Macherla, V.R.R., Neuteboom, S.T.C.: WO2006060809 (2006).
90. Samuel, D., Atsushi, E.: WO2006124902 (2006).
91. Ling, T.T., Macherla, V.R.R., Potts, B.C., Manam, R.R., Mcarthur, K.: WO2007117591 (2007).
92. Potts, B., Singh, R., Chu, J.J., Mai, B.V., Reddinger, N., Billstrom, C.: WO2008095195 (2008).
93. Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV related Kaposi's sarcoma. AIDS (Hagerstown) 1998; 12: F45-F49.
94. Panjonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization on non-HIV-associated human cancer cells. Cancer Res 2002; 62: 5230-5235.
95. Piccinini M, Rinaudo MT, Chiapello N, et al. The human 26S proteasome is a target of antiviral agents. AIDS 2002; 16: 693-700.
96. Schubert U, Ott DE, Chertova EN, et al. Proteasome inhibition interferes with gag polyprotein processing, release and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci USA 2000; 97: 13057-13062.
97. Jacque JM, Fernandez B, Arenzana SF, et al. Permanent occupancy of the immunedeficiency virus type 1 enhancer by NF-B is needed for persistent viral replication in monocytes. J Virol 1996; 70: 2930-2938.
98. Zhou, H.J., Laidig, G.J., Shenk, K.D., Sun, C.M.: WO2008140782 (2008).
99. Ulrich, S., Stephan, L., Oliver, P.: WO2007093635 (2007).
100. Proesch, S., Volk, H.D., Krueger, D.: US20070042967 (2007).
101. Ulrich, S., Hans, W., Huseyin, S.: US20050203029 (2005).
102. Ulrich, S., Hans, W., Uwe, T., Husseyin, S., Alexij, P., Eveleyn, S., Heinz, H., Reinhardt, W.: US20040106539 (2004).
103. Oliver, P., Stephan, P., Hans, H.S., Stephan, L.: WO2004060360 (2004).
104. Ulrich, S., Hans, W., Uwe, T., Husseyin, S., Alexij, P., Eveleyn, S., Heinz, H., Reinhardt, W.: WO0230455 (2002).
105. Wu, J.P., Wang, X.: US20020049157 (2002).
106. Pomper, M.G., Ambinder, R.F., Liu, J.K., Chong, C.: WO2008124197 (2008).
107. Meier, T., Buyse, G.: WO2006100017 (2006).
108. Stangl, V., Stangl, K., Lorenz, M.: US2006019977 (2006).
109. Kem, D.C., Patterson, E.: WO2005023187 (2005).
110. Stangl, V., Stangl, K., Lorenz, M.: WO2004012732 (2004).
111. Stangl, K., Meiners, S., Hocher, B.: WO2004011019 (2004).
112. Stangl, K., Meiners, S., Laule, M., Guenther, C.; Kloetzel, P.: DE10040742 (2002).
113. Plamondon, L., Grenier, L., Adams, J., Gupta, S.L.: WO9835691 (1998).
114. Purintrapiban J, Wang MC, Forsberg NE. Degradation of sarcomeric and cytoskeletal proteins in cultured skeletal muscle cells. Comp Biochem Physiol B Biochem Mol Biol 2003; 136: 393-401.
115. Solomon V, Goldberg AL. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 1996; 271: 26690-26697.
116. Zolk O, Schenke C, Sarikas A. The ubiquitin-proteasome system: Focus on the heart. Cardiovasc Res 2006; 70: 410-421.
117. Bao J, Sato K, Li M, et al. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am J Physiol Heart Circ Physiol 2001; 281: H2612-H2618.
118. Eble DM, Spragia ML, Ferguson AG, Samarel AM. Sarcomeric myosin heavy chain is degraded by the proteasome. Cell Tissue Res 1999; 296: 541-548.
119. Di NM, Papa F. The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response. Curr Opin Investig Drugs 2003; 4: 1333-1342.
120. Di NM, Papa F. MLN-519 (Millennium/PAION). Curr Opin Investig Drugs 2003; 4: 333-341.
121. Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001; 72: 196-202.
122. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002; 105: 483-489.
123. Luss H, Schmitz W, Neumann J. A proteasome inhibitor confers cardioprotection. Cardiovasc Res 2002; 54: 140-151.
124. Stangl K, Gunther C, Frank T, et al. Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem Biophys Res Commun 2002; 291: 542-549.
125. Taha D, Umpaichitra V, Banerji MA, Castells S. Type 2 diabetes mellitus in African-American adolescents: impaired beta-cell function in the face of severe insulin resistance. J Pediatr Endocrinol Metab 2006; 19: 135-142.
126. Vivian EM. Type 2 diabetes in children and adolescents-the next epidemic? Curr Med Res Opin 2006; 22: 297-306.
127. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28: 2130-2135.
128. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 2347-2355.
129. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.
130. Ferroni P, Guagnano MT, Manigrasso MR, Ciabattoni G, Davi G. Increased plasminogen activator inhibitor-1 levels in android obesity: correlation with oxidative stress. J Thromb Haemost 2005; 3: 1086-1087.
131. Deans KA, Sattar N. Anti-inflammatory drugs and their effects on type 2 diabetes. Diabetes Technol Ther 2006; 8: 18-27.
132. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006; 22: 4-10.
133. Wu L, Nicholson W, Knobel SM, et al. Oxidative stress is a mediator of glucose toxicity in insulin-secreting pancreatic islet cell lines. J Biol Chem 2004; 279:12126-12134.
134. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
135. Chen H. Cellular inflammatory responses: novel insights for obesity and insulin resistance. Pharmacol Res 2006; 53: 469-477.
136. Feve B, Bastard JP, Vidal H. Relationship between obesity, inflammation and insulin resistance: new concepts. C R Biol 2006; 329: 587-597.
137. de Rekeneire N, Peila R, Ding J, et al. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 2006; 29: 1902-1908.
138. Esposito K, Giugliano G, Scuderi N, Giugliano D. Role of adipokines in the obesity-inflammation relationship: the effect of fat removal. Plast Reconstr Surg 2006; 118: 1048-1057.
139. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326.
140. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280.
141. Buckingham RE. Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol Res 2005; 33: 167-170.
142. Takebayashi K, Matsumoto S, Wakabayashi S, et al. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism 2005; 54: 1225-1229.
143. Tortoriello, D., Weisberg, S. P.: WO2008063513 (2008).
144. Brand, S.J.: WO2007084651 (2007).
145. Kaushal, S., Grant, M.G.: WO2007014323 (2007).
146. Freissmuth, M., Kirpenko, T., Nanoff, C., Korkhov, V.M.: WO2007002972 (2007).
147. Nakajima, H., Fujiwara, H., Fujita, K., Furuichi, Y., Shimbara, N.: WO2006129587 (2006).
148. Barsoum, J., Du, Z.J.: WO2006113572 (2006).
149. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-6854.
150. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high risk or premalignant lesions. Anticancer Res 2001; 21: 2895-2900.
151. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980; 71: 632-634.
152. Portero OM, Pamplona R, Ruiz MC, Cabiscol E, Prat J, Bellmunt MJ. Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes 1999; 48: 2215-2220.
153. Merforth S, Osmers A, Dahlmann B. Alterations of proteasome activities in skeletal muscle tissue of diabetic rats. Mol Biol Rep 1999; 26: 83-87.
154. Dahlmann B, Kuehn L, Rutschmann M, Reinauer H. Purification and characterization of a multicatalytic high molecular mass proteinase from rat skeletal muscle. Biochem J 1985; 228: 161-170.
155. Merforth S, Kuehn L, Osmers A, Dahlmann B. Alteration of 20S proteasome-subtypes and proteasome activator PA28 in skeletal muscle of rat after induction of diabetes mellitus. Int J Biochem Cell Biol 2003; 35: 740-748.
156. Alves RA, Gregori L, Figueiredo PME. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci 1998; 21: 516-520.
157. Bingol B, Schuman EM. Synaptic protein degradation by the ubiquitin proteasome system. Curr Opin Neurobiol 2005; 5: 536-541.
158. Bingol B, Schuman EM. Activity-dependent dynamics and sequestration of proteasomes in dendritic spines. Nature 2006; 441: 1144-1148.
159. Ehlers MD. Eppendorf 2003 prize-winning essay. Ubiquitin and the deconstruction of synapses. Science 2003; 302: 800-801.
160. Jiang C, Schuman EM. Regulation and function of local protein synthesis in neuronal dendrites. Trends Biochem Sci 2002; 27: 506-513.
161. Lee SH, Choi JH, Lee N, et al. Synaptic protein degradation underlies destabilization of retrieved fear memory. Science 2008; 319: 1253-1256.
162. Ehlers MD. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci 2003; 6: 231-232.
163. Sisodia SS. Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial? Cell 1998; 95: 1-4.
164. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-108.
165. Larsen CN, Krantz BA, Wilkinson KD. Substrate specificity of deubiquitinating enzymes: Ubiquitin C-terminal hydrolases. Biochemistry 1998; 37: 3358-3368.
166. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradia MM. Degradation of -synuclein by proteasome. J Biol Chem 1999; 274: 33855-33858.
167. McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002; 81: 301-306.
168. Matsuura T, Sutcliffe JS, Fang P, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997; 15: 74-77.
169. Kim, K.B., Ho, Y.K.: US20080064659 (2008).
170. Shenk, K.D., Parlati, F., Zhou, H.J., Sylvain, C., Smyth, M.S., Bennett, M.K., Laidig, G.J.: US20070293465 (2007).
171. Gupta, S.K.: US20060269494 (2006).
172. Michael, K., Serguei, M.: US20060210538 (2006).
173. Mark, K., Bennett, C.J., Kirk, S.D.: US20060193844 (2006).
174. He, Z.G., Zhai, Q.W., Wang, J., Watts, R., Hoopfer, E., Luo, L.Q.: WO2005014783 (2005).
175. Tennore, R., Sean, S.: US20040138153 (2004).
176. Campbell DS, Holt CE. Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron 2001; 32: 1013-1026.
177. Campbell DS, Holt CE. Apoptotic pathway and MAPKs differentially regulate chemotropic responses of retinal growth cones. Neuron 2003; 37: 939-952.
178. Jack, A.: WO200612752 (2006).
179. Zetterberg M, Petersen A, Sjostrand J, Karlsson J. Proteasome activity in human lens nuclei and correlation with age, gender and severity of cataract. Curr Eye Res 2003; 27: 45-53.
180. Chondrogianni N, Stratford FLL, Trougakos IP, Friguet B, Rivett AJ, Gonos ES. Central role of the proteasome in senescence and survival of human fibroblasts. J Biol Chem 2003; 278: 28026-28037.
181. Chondrogianni N, Gonos ES. Proteasome inhibition induces a senescence-like phenotype in primary human fibroblasts cultures. Biogerontology 2004; 5: 55-61.